|
Tuesday, May 1, 2012
MD Biosciences
A Rapid 10 day preclinical efficacy study that produces lesions highly representative of human psoriatic lesions.
Wednesday, May 2, 2012, St. Paul, MN – The most common models for evaluating skin-related inflammation are time... Read More
|
|
Thursday, Aug 11, 2011
MD Biosciences
MD Biosciences , a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of Parkinson's Disease (PD) . The 6-OHDA and acute MPTP models for PD have been well characterized with the underlying mechanisms of toxicity... Read More
|
|
Wednesday, Jul 13, 2011
MD Biosciences
MD Biosciences, a preclinical CRO focused in pain and inflammations, has released a new eBook discussing the interactions between the nervous and immune systems and the drug targets that may lie in the overlap. This newly published eBook... Read More
|
|
Thursday, Feb 3, 2011
MD Biosciences
MD Biosciences, a global biotechnology company focused in inflammations research, has optimized ArthritoMabTM Antibody Cocktail for the induction of arthritis in C57Bl/6. Using the optimized ArthritoMab Antibody Cocktail ,... Read More
|
|
Wednesday, Jun 16, 2010
MD Biosciences
Wednesday, June 16, 2010, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of myocardial infarct (MI). The occlusion-induced myocardial infarct model is a well-known... Read More
|